Search

Author/Creator An, Ho Jung

1. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14‐01). Issue 11 (19th January 2017)

Authors:
Kim, Youjin; Lee, Su Jin; Lee, Ji Yun; Lee, Se‐Hoon; Sun, Jong‐Mu; Park, Keunchil; An, Ho Jung; Cho, Jae Yong; Kang, Eun Joo; Lee, Ha‐Young; Kim, Jinsoo; Keam, Bhumsuk; Kim, Hye Ryun; Lee, Kyoung Eun; Choi, Moon Young; Lee, Ki Hyeong; Ahn, Myung‐Ju
Journal:
Cancer
Issue:
Volume 123:Issue 11(2017)
Page Start:
1958
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study. (27th December 2020)

Authors:
Park, Hyung Soon; Won, Hye Sung; An, Ho Jung; Cho, Sung Shim; Kim, Hyun Ho; Sun, Der Sheng; Ko, Yoon Ho; Shim, Byoung Yong
Journal:
Cancer medicine
Issue:
Volume 10:Number 3(2021)
Page Start:
1057
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Human papillomavirus‐stratified analysis of the prognostic role of miR‐21 in oral cavity and oropharyngeal squamous cell carcinoma. (19th September 2014)

Authors:
Ko, Yoon Ho; Won, Hye Sung; Sun, Der Sheng; An, Ho Jung; Jeon, Eun Kyoung; Kim, Min Sik; Lee, Han Hong; Kang, Jin Hyoung; Jung, Chan Kwon
Journal:
Pathology international
Issue:
Volume 64:Number 10(2014:Oct.)
Page Start:
499
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. (December 2022)

Authors:
Lee, Jii Bum; Park, Hyung Soon; Choi, Su Jin; Heo, Seong Gu; An, Ho Jung; Kim, Hye Ryun; Hong, Min Hee; Lim, Sun Min; Chang, Kyle; Quinn, Katie; Odegaard, Justin; Shim, Byoung Yong; Cho, Byoung Chul
Journal:
Therapeutic advances in medical oncology
Issue:
Volume 14(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2019)

Authors:
Nakagawa, Kazuhiko; Garon, Edward B; Seto, Takashi; Nishio, Makoto; Ponce Aix, Santiago; Paz-Ares, Luis; Chiu, Chao-Hua; Park, Keunchil; Novello, Silvia; Nadal, Ernest; Imamura, Fumio; Yoh, Kiyotaka; Shih, Jin-Yuan; Au, Kwok Hung; Moro-Sibilot, Denis; Enatsu, Sotaro; Zimmermann, Annamaria; Frimod...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 12(2019)
Page Start:
1655
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. (September 2019)

Authors:
Kim, Dong-Wan; Lee, Dae Ho; Han, Ji-Youn; Lee, Jongseok; Cho, Byoung Chul; Kang, Jin Hyoung; Lee, Ki Hyeong; Cho, Eun Kyung; Kim, Jin-Soo; Min, Young Joo; Cho, Jae Yong; An, Ho Jung; Kim, Hoon-Gu; Lee, Kyung Hee; Kim, Bong-Seog; Jang, In-Jin; Yoon, Seonghae; Han, OakPil; Noh, Young Su; Hong, Ka Y...
Journal:
Lung cancer
Issue:
Volume 135(2019)
Page Start:
66
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Stage-Stratified Analysis of Prognostic Significance of Bax-Interacting Factor-1 Expression in Resected Colorectal Cancer. (23rd September 2013)

Authors:
Ko, Yoon Ho; Cho, Young-Seok; Won, Hye Sung; An, Ho Jung; Sun, Der Sheng; Hong, Soon Uk; Park, Jin Hee; Lee, Myung Ah
Other Names:
Konger Raymond L. Academic Editor.
Journal:
BioMed research international
Issue:
Volume 2013(2013)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Issue 11 (November 2020)

Authors:
Wu, Yi-Long; Cheng, Ying; Zhou, Jianying; Lu, Shun; Zhang, Yiping; Zhao, Jun; Kim, Dong-Wan; Soo, Ross Andrew; Kim, Sang-We; Pan, Hongming; Chen, Yuh-Min; Chian, Chih-Feng; Liu, Xiaoqing; Tan, Daniel Shao Weng; Bruns, Rolf; Straub, Josef; Johne, Andreas; Scheele, Jürgen; Park, Keunchil; Yang, Jam...
Journal:
Lancet
Issue:
Volume 8:Issue 11(2020)
Page Start:
1132
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗